Is AVITA Medical Inc (RCEL) Overvalued After 5.9% Rally? GF Value Says Overvalued
On October 02, 2026, AVITA Medical Inc (RCEL) shares rose 5.9% to a current price of $12.72, within a 52-week range of $3.22 to $12.76. The stock has shown impr
RCEL - Avita Medical Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$11.50
DETAILS
HIGH:
$12.00
LOW:
$11.00
MEDIAN:
$11.50
CONSENSUS:
$11.50
DOWNSIDE:
11.57%
Stock News
NewEdge Advisors LLC Purchases 62,046 Shares of Avita Medical Inc. $RCEL
NewEdge Advisors LLC grew its position in Avita Medical Inc. (NASDAQ: RCEL) by 71.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 148,931 shares of the company's stock after purchasing an additional 62,046 shares during the quarter. NewEdge Advisors LLC owned
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer | New York Morgan Stanley 24th Annual Global Healthcare Conference – Wednesday, September 16, 2026 | 1:05 p.m.
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
AVITA Medical: Favorable Reimbursements For Skin Wound Care
AVITA Medical's reimbursement is now becoming more predictable. I believe this removes one of their main adoption barriers going forward. The RECELL GO international rollout and PermeaDerm's positive clinical economics also broaden RCEL's long-term potential. Management said they should reach their cash flow breakeven target by Q4 2026, which would further derisk the stock as a whole.
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
Avita Medical NASDAQ: RCEL presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft.
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinical outcomes and a 96% reduction in preparation time.
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets.
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
Avita Medical NASDAQ: RCEL expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference.
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on August 12, 2026, at 4:00 p.m.
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it will be participating at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026.
Avita Medical Q2 Earnings Call Highlights
Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 18% from a year earlier and 13% sequentially, as growth in its RECELL wound-care product and newer portfolio offerings supported results.
AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript
AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
VALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the second quarter ended June 30, 2026.
AVITA Medical to Announce Second Quarter 2026 Financial Results
VALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2026 financial results after the close of the U.S. financial markets on Thursday, August 6, 2026.
Avita Medical (RCEL) Upgraded to Buy: Here's Why
Avita Medical (RCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Price Targets
Avita Medical price target raised to $12 from $8 at Lake Street
$12.00
(was $10.48)
Lake Street
Avita Medical Ltd. (RCEL) PT Raised to $11 at BTIG
$11.00
(was $9.85)
Ryan Zimmerman
·
BTIG
BTIG Upgrades Avita Medical Ltd. (RCEL) to Buy
$7.00
(was $4.75)
Ryan Zimmerman
·
BTIG
Avita Medical upgraded to Buy from Hold at Lake Street
$6.00
(was $4.36)
Lake Street
Avita Medical stock pullback creates buying opportunity, says Northland
$10.00
(was $3.86)
Northland Securities
Avita Medical price target raised to $3.50 from $3 at Lake Street
$3.50
(was $3.60)
Lake Street
Avita Medical downgraded to Hold from Buy at Lake Street
$4.00
(was $5.38)
Frank Takkinen
·
Lake Street
Avita Medical price target lowered to $14 from $20 at Lake Street
$14.00
(was $14.06)
Brooks O'Neil
·
Lake Street
Piper Sandler Downgrades Avita Medical Ltd. (RCEL) to Neutral
$9.00
(was $8.35)
Matt O'Brien
·
Piper Sandler